Table 3:
Characteristics of included studies with heart failure event definitions (10 studies).
| Author | Year | Population(n) | Intervention | Comparator | Duration | Primary outcome | Does primary outcome include a heart failure event? | Adjudication | Heart failureevent rateaactive (%)comparator (%) |
|---|---|---|---|---|---|---|---|---|---|
| Chertow [37] | 2012 | HD(3883) | Cinacalcet | Placebo | median 21.1/17.5 months study drug exposure | Time to death or first nonfatal cardiovascular event | Yes | Yes | 206/1948 (10.6%)6.01/100 PY236/1935 (12.2%)8.36/100 PY |
| Cice [38] | 2010 | HD(332) | Telmisartan | Placebo | mean 35.5 (SD 8.5) months,median 36 months | (i) All-cause mortality(ii) Cardiovascular death(iii) Hospital admission for management of worsening congestive heart failure | Yes | No | 56/165 (33.9%)11.48/100 PY92/167 (55.1%)18.62/100 PY |
| MacDougall [17] | 2019 | HD(2141) | High dose IV iron, proactive | Low dose IV iron, reactive | median 2.1 years | Nonfatal MI, nonfatal stroke, hospitalization for heart failure, death from any cause | Yes | Yes | 51/1093 (4.7%)2.22/100 PY70/1048 (6.7%)3.18/100 PY |
| Matmsumoto [39] | 2014 | HD(309) | Spironolactone | Control | 3 years | Death from cardiovascular events or hospitalization for cardiovascular events | Yes | No | 1/147 (0.7%)3/152 (2.0%) |
| Parfrey [40] | 2005 | HD(596) | Haemoglobin target13.5–14.5 g/dl | Haemoglobin target9.5–11.5 g/dl | 96 weeks | Left ventricular volume index | No | No | 11/296 (3.7%)12/300 (4.0%)(efficacy)11/296 (3.7%)19/300 (6.3%)(adverse event) |
| Shoji [16] | 2018 | HD(1289) | Oral alfacalcidiol | Control | mean 3.6 yearsmedian 4.0 years | Fatal and nonfatal cardiovascular events, coronary intervention of bypass grafting, lower limb artery intervention, or bypass grafting | Yes | Yes | 15/488 (3.1%)0.85/100 PY14/476 (2.9%)0.82/100 PY |
| Suzuki [41] | 2008 | HD(366) | Angiotensinogen receptor blocker | Control | 36 months | Fatal and nonfatal cardiovascular events | Yes | No | 14/180 (7.8%)29/180 (16.1%) |
| Takahashi [42] | 2006 | HD(80) | Candesartan | Control | mean 19.4 (SD 1.2) months | Cardiovascular events | Yes | Yes | 5/43 (11.6%)7.19/100 PY11/37 (29.7%)18.39/100 PY |
| Walsh [15] | 2015 | HD(154) | Eplerenone | Placebo | 13 weeks | Permanent discontinuation of study drug due to hyperkalaemia or significant hypotension | No | No | Not reported |
| Zannad [43] | 2006 | HD(397) | Fosinopril | Placebo | 24 months | Cardiovascular events | Yes | Yes | 54/397 (13.6%)(pooled) |
aHeart failure event rate calculated if mean/median follow-up reported